The Q1 earnings report for NeoGenomics (NASDAQ:NEO) was released on Tuesday, April 30, 2024 at 07:30 AM.

Here's what investors need to know about the latest announcement.

Earnings

NeoGenomics beat estimated earnings by 60.0%, reporting an EPS of $-0.02 versus an estimate of $-0.05.

Revenue was up $19.02 million from the same period last year.

Analysis of Past Earnings

Last quarter the company beat on EPS by $0.05 which was followed by a 12.0% increase in the share price the next day.

Here's a look at NeoGenomics's past performance:

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Guidance

NeoGenomics management provided guidance for FY 2024, expecting earnings between $0.0 and $0.04 per share.

Recent Earnings Releases from Competitors

With NeoGenomics's earnings data in hand, it's essential to compare its metrics to those of similar companies, including BrightSpring Health, Guardant Health, and R1 RCM.

Competitors Quarterly Earnings and Stock Performance Analysis

This analysis provides insights into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with the corresponding stock prices at the close of the announcement day and the open of the following trading day.

Analyzing Peer Revenue Discrepancy: Estimated vs. Announced

The comparison table below presents estimated and announced revenue figures for NeoGenomics's peers. This comparison provides insights into the revenue performance of these companies, offering valuable context for understanding their financial standing within the industry.

To track all earnings releases for NeoGenomics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.